综述

免疫细胞调控心肌缺血损伤后再生的研究进展

  • 赵旻炅 ,
  • 陈铃芳 ,
  • 胡苗清 ,
  • 冯杰 ,
  • 聂宇
展开
  • 1.中国医学科学院阜外医院心血管疾病全国重点实验室,国家心血管病中心,北京 102300
    2.郑州大学华中阜外医院,阜外华中心血管病医院,河南心血管病中心,国家心血管病中心华中分中心,再生医学重点实验室,郑州 450046
聂 宇,研究员,博士;电子信箱:nieyuniverse@126.com

收稿日期: 2025-07-31

  录用日期: 2025-12-01

  网络出版日期: 2026-03-30

基金资助

国家自然科学基金(82300325);国家心血管病中心华中分中心自主课题(2024-FZX04);心血管疾病全国重点实验室资助项目(2025GZZD-03);心血管疾病全国重点实验室资助项目(2025GZQN-04);中国医学科学院中央级公益性科研院所基本科研业务费(2023-PT310-03)

Research progress on immune cells regulation of cardiac regeneration after ischemic myocardial injury

  • Zhao Minjiong ,
  • Chen Lingfang ,
  • Hu Miaoqing ,
  • Feng Jie ,
  • Nie Yu
Expand
  • 1.State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 102300, China
    2.National Health Commission Key Laboratory of Cardiovascular Regenerative Medicine, Central China Subcenter of National Center for Cardiovascular Disease, Henan Cardiovascular Disease Center, Fuwai Center-China Cardiovascular Hospital, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou 450046, China
Nie Yu, E-mail: nieyuniverse@126.com.

Received date: 2025-07-31

  Accepted date: 2025-12-01

  Online published: 2026-03-30

Supported by

National Natural Science Foundation of China(82300325);The Grants from Henan Cardiovascular Disease Center (Central China Subcenter of National Center for Cardiovascular Diseases)(2024-FZX04);The State Key Laboratory of Cardiovascular Disease(2025GZZD-03);The Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences(2023-PT310-03)

摘要

缺血性心脏病特别是心肌梗死可导致大量心肌细胞不可逆性丧失。由于成年哺乳动物心肌细胞增殖能力高度受限,心肌受损区域通常被纤维化瘢痕组织取代,进而引发心室重构和心力衰竭,对健康造成严重威胁。近年来,诱导内源性心肌再生已成为改善心肌损伤预后的潜在治疗策略,而免疫调控机制在其中发挥核心作用。心肌损伤后,机体迅速启动复杂的炎症免疫级联反应。研究表明,炎症反应的时序与强度是决定组织修复结局的关键。在具有再生能力的模型中炎症反应启动迅速且消退及时,而成年个体则常出现炎症消退延迟与免疫失调,导致纤维化瘢痕形成。在此过程中,多种免疫细胞(如巨噬细胞、中性粒细胞、T细胞等)凭借其高度异质性特征、时序性浸润模式及微环境特异性分布,通过细胞间直接接触或旁分泌途径等方式,精细调控心肌细胞增殖与组织修复进程。这些免疫调控机制相互协调,形成一个动态促进心肌再生的交互网络。该综述系统阐述了各类免疫细胞在心肌损伤后再生修复过程中的应答特征及其调控机制,以期为缺血性心脏病的临床治疗提供新的思路与策略。

本文引用格式

赵旻炅 , 陈铃芳 , 胡苗清 , 冯杰 , 聂宇 . 免疫细胞调控心肌缺血损伤后再生的研究进展[J]. 上海交通大学学报(医学版), 2026 , 46(3) : 368 -376 . DOI: 10.3969/j.issn.1674-8115.2026.03.011

Abstract

Ischemic heart disease, particularly myocardial infarction, can lead to extensive and irreversible loss of cardiomyocytes. Due to the highly restricted proliferative capacity of cardiomyocytes in adult mammals, the damaged myocardial regions are typically replaced by fibrotic scar tissue, leading to ventricular remodelling and heart failure, which poses a serious threat to health. In recent years, promoting endogenous cardiac regeneration has emerged as an attractive strategy to improve outcomes following myocardial injury, and immune regulatory mechanisms play a central role in this process. Upon myocardial injury, the body initiates a complex inflammatory immune cascade. Studies have shown that the timing and magnitude of the inflammatory responses are critical determinants of tissue repair outcomes. In regenerative models, inflammatory responses initiate rapidly and resolve promptly, whereas in adults, inflammation often persists, and immune dysregulation leads to fibrotic scar formation. During this process, various immune cells (such as macrophages, neutrophils, and T cells) exert precise regulation on cardiomyocyte proliferation and tissue repair through direct intercellular contact or paracrine signalling pathways. This is achieved via their highly heterogeneous characteristics, sequential infiltration patterns, and microenvironment-specific distribution. These immune regulatory mechanisms coordinate to form a dynamic and interactive network that promotes cardiac regeneration. This review systematically summarises the response characteristics and regulatory mechanisms of various immune cells during the regenerative repair process following myocardial injury, aiming to provide novel insights and strategies for the clinical treatment of ischemic heart disease.

参考文献

[1] Zhang L, Tong Z, Han R Z, et al. Global, regional, and national burdens of ischemic heart disease attributable to smoking from 1990 to 2019[J]. J Am Heart Assoc, 2023, 12(3): e028193.
[2] Byrne R A, Rossello X, Coughlan J J, et al. 2023 ESC guidelines for the management of acute coronary syndromes[J]. Eur Heart J, 2023, 44(38): 3720-3826.
[3] Rao S V, O′Donoghue M L, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J]. Circulation, 2025, 151(13): e771-e862.
[4] Bergmann O, Zdunek S, Felker A, et al. Dynamics of cell generation and turnover in the human heart[J]. Cell, 2015, 161(7): 1566-1575.
[5] Poss K D, Wilson L G, Keating M T. Heart regeneration in zebrafish[J]. Science, 2002, 298(5601): 2188-2190.
[6] Porrello E R, Mahmoud A I, Simpson E, et al. Transient regenerative potential of the neonatal mouse heart[J]. Science, 2011, 331(6020): 1078-1080.
[7] Derks W, Rode J, Collin S, et al. A latent cardiomyocyte regeneration potential in human heart disease[J]. Circulation, 2025, 151(3): 245-256.
[8] Hilgendorf I, Frantz S, Frangogiannis N G. Repair of the infarcted heart: cellular effectors, molecular mechanisms and therapeutic opportunities[J]. Circ Res, 2024, 134(12): 1718-1751.
[9] Cortada E, Yao J, Xia Y, et al. Cross-species single-cell RNA-seq analysis reveals disparate and conserved cardiac and extracardiac inflammatory responses upon heart injury[J]. Commun Biol, 2024, 7(1): 1611.
[10] Han C Y, Nie Y, Lian H, et al. Acute inflammation stimulates a regenerative response in the neonatal mouse heart[J]. Cell Res, 2015, 25(10): 1137-1151.
[11] Dick S A, Wong A, Hamidzada H, et al. Three tissue resident macrophage subsets coexist across organs with conserved origins and life cycles[J]. Sci Immunol, 2022, 7(67): eabf7777.
[12] Weinberger T, Denise M, Joppich M, et al. Resident and recruited macrophages differentially contribute to cardiac healing after myocardial ischemia[J]. eLife, 2024, 12: RP89377.
[13] Chen R K, Zhang H R, Tang B T, et al. Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets[J]. Signal Transduct Target Ther, 2024, 9(1): 130.
[14] Bajpai G, Schneider C, Wong N, et al. The human heart contains distinct macrophage subsets with divergent origins and functions[J]. Nat Med, 2018, 24(8): 1234-1245.
[15] Li Y D, Feng J, Song S, et al. gp130 controls cardiomyocyte proliferation and heart regeneration[J]. Circulation, 2020, 142(10): 967-982.
[16] Fu M Z, Jia S T, Xu L H, et al. Single-cell multiomic analysis identifies macrophage subpopulations in promoting cardiac repair[J]. J Clin Invest, 2024, 134(19): e175297.
[17] Jung M, Ma Y G, Iyer R P, et al. IL-10 improves cardiac remodeling after myocardial infarction by stimulating M2 macrophage polarization and fibroblast activation[J]. Basic Res Cardiol, 2017, 112(3): 33.
[18] Isidoro C A, Deniset J F. The role of macrophage subsets in and around the heart in modulating cardiac homeostasis and pathophysiology[J]. Front Immunol, 2023, 14: 1111819.
[19] Zhou Y, Stevis P E, Cao J, et al. Structures of complete extracellular assemblies of type I and type Ⅱ oncostatin M receptor complexes[J]. Nat Commun, 2024, 15(1): 9776.
[20] Liu S J, Li R G, Martin J F. The cell-autonomous and non-cell-autonomous roles of the Hippo pathway in heart regeneration[J]. J Mol Cell Cardiol, 2022, 168: 98-106.
[21] Xiao Y, Zhang H, Liu X, et al. Medium from human iPSC-derived primitive macrophages promotes adult cardiomyocyte proliferation and cardiac regeneration[J]. Nat Commun, 2025, 16(1): 3012.
[22] Jiang Y L, Niu S W, Lin Z, et al. Injectable hydrogel with dual-sensitive behavior for targeted delivery of oncostatin M to improve cardiac restoration after myocardial infarction[J]. J Mater Chem B, 2022, 10(34): 6514-6531.
[23] Li Y D, Li H T, Pei J Q, et al. Transplantation of murine neonatal cardiac macrophage improves adult cardiac repair[J]. Cell Mol Immunol, 2021, 18(2): 492-494.
[24] Sun K, Li Y Y, Jin J. A double-edged sword of immuno-microenvironment in cardiac homeostasis and injury repair[J]. Signal Transduct Target Ther, 2021, 6(1): 79.
[25] Miyake K, Ito J, Takahashi K, et al. Single-cell transcriptomics identifies the differentiation trajectory from inflammatory monocytes to pro-resolving macrophages in a mouse skin allergy model[J]. Nat Commun, 2024, 15(1): 1666.
[26] Trzebanski S, Kim J S, Larossi N, et al. Classical monocyte ontogeny dictates their functions and fates as tissue macrophages[J]. Immunity, 2024, 57(6): 1225-1242.e6.
[27] Gallerand A, Dolfi B, Stunault M I, et al. Glucose metabolism controls monocyte homeostasis and migration but has no impact on atherosclerosis development in mice[J]. Nat Commun, 2024, 15(1): 9027.
[28] Thierry G R, Baudon E M, Bijnen M, et al. Non-classical monocytes scavenge the growth factor CSF1 from endothelial cells in the peripheral vascular tree to ensure survival and homeostasis[J]. Immunity, 2024, 57(9): 2108-2121.
[29] Minton K. Non-classical monocytes have the support of the whole vascular tree[J]. Nat Rev Immunol, 2024, 24(9): 619.
[30] Nahrendorf M, Swirski F K, Aikawa E, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions[J]. J Exp Med, 2007, 204(12): 3037-3047.
[31] Chen Z W, Cai D C, Xie Y F, et al. Triiodothyronine induces a proinflammatory monocyte/macrophage profile and impedes cardiac regeneration[J]. J Mol Cell Cardiol, 2024, 191: 7-11.
[32] He S, Chousterman B G, Fenn A, et al. Lp-PLA2 antagonizes left ventricular healing after myocardial infarction by impairing the appearance of reparative macrophages[J]. Circ Heart Fail, 2015, 8(5): 980-987.
[33] Rizzo G, Gropper J, Piollet M, et al. Dynamics of monocyte-derived macrophage diversity in experimental myocardial infarction[J]. Cardiovasc Res, 2023, 119(3): 772-785.
[34] Kubota A, Frangogiannis N G. Macrophages in myocardial infarction[J]. Am J Physiol Cell Physiol, 2022, 323(4): C1304-C1324.
[35] Kim C, Kim H, Sim W S, et al. Spatiotemporal control of neutrophil fate to tune inflammation and repair for myocardial infarction therapy[J]. Nat Commun, 2024, 15(1): 8481.
[36] Cohen C D, Rousseau S T, Bermea K C, et al. Myocardial immune cells: the basis of cardiac immunology[J]. J Immunol, 2023, 210(9): 1198-1207.
[37] Kologrivova I, Shtatolkina M, Suslova T, et al. Cells of the immune system in cardiac remodeling: main players in resolution of inflammation and repair after myocardial infarction[J]. Front Immunol, 2021, 12: 664457.
[38] Sreejit G, Abdel-Latif A, Athmanathan B, et al. Neutrophil-derived S100A8/A9 amplify granulopoiesis after myocardial infarction[J]. Circulation, 2020, 141(13): 1080-1094.
[39] Zhou X H, Zhang C Y, Wu X Y, et al. Dusp6 deficiency attenuates neutrophil-mediated cardiac damage in the acute inflammatory phase of myocardial infarction[J]. Nat Commun, 2022, 13(1): 6672.
[40] Wang X K, Xu Y, Yu C Q, et al. Periodontitis-related myocardial fibrosis by expansion of collagen-producing SiglecF+ neutrophils[J]. Eur Heart J, 2025, 46(23): 2223-2238.
[41] He L, Liu R Q, Yue H H, et al. Interaction between neutrophil extracellular traps and cardiomyocytes contributes to atrial fibrillation progression[J]. Signal Transduct Target Ther, 2023, 8(1): 279.
[42] Zhang N, Aiyasiding X, Li W J, et al. Neutrophil degranulation and myocardial infarction[J]. Cell Commun Signal, 2022, 20(1): 50.
[43] Petzold T, Zhang Z, Ballesteros I, et al. Neutrophil “plucking” on megakaryocytes drives platelet production and boosts cardiovascular disease[J]. Immunity, 2022, 55(12): 2285-2299.
[44] Thakur M, Junho C V C, Bernhard S M, et al. NETs-induced thrombosis impacts on cardiovascular and chronic kidney disease[J]. Circ Res, 2023, 132(8): 933-949.
[45] Mangold A, Ondracek A S, Hofbauer T M, et al. Culprit site extracellular DNA and microvascular obstruction in ST-elevation myocardial infarction[J]. Cardiovasc Res, 2022, 118(8): 2006-2017.
[46] Chalise U, Becirovic-Agic M, Lindsey M L. Neutrophil crosstalk during cardiac wound healing after myocardial infarction[J]. Curr Opin Physiol, 2021, 24: 100485.
[47] Santos-Zas I, Lemarié J, Zlatanova I, et al. Cytotoxic CD8+ T cells promote granzyme B-dependent adverse post-ischemic cardiac remodeling[J]. Nat Commun, 2021, 12(1): 1483.
[48] Alcaide P, Kallikourdis M, Emig R, et al. Myocardial inflammation in heart failure with reduced and preserved ejection fraction[J]. Circ Res, 2024, 134(12): 1752-1766.
[49] Wang D Z, Weng X Y, Yue W H, et al. CD8 T cells promote heart failure progression in mice with preexisting left ventricular dysfunction[J]. Front Immunol, 2024, 15: 1472133.
[50] Alshoubaki Y K, Nayer B, Lu Y Z, et al. Tregs delivered post-myocardial infarction adopt an injury-specific phenotype promoting cardiac repair via macrophages in mice[J]. Nat Commun, 2024, 15(1): 6480.
[51] Sun L N, Su Y H, Jiao A J, et al. T cells in health and disease[J]. Signal Transduct Target Ther, 2023, 8(1): 235.
[52] Li J T, Liang C, Yang K Y, et al. Specific ablation of CD4+ T-cells promotes heart regeneration in juvenile mice[J]. Theranostics, 2020, 10(18): 8018-8035.
[53] Dolejsi T, Delgobo M, Schuetz T, et al. Adult T-cells impair neonatal cardiac regeneration[J]. Eur Heart J, 2022, 43(28): 2698-2709.
[54] Bakhshian Nik A, Alvarez-Argote S, O′Meara C C. Interleukin 4/13 signaling in cardiac regeneration and repair[J]. Am J Physiol Heart Circ Physiol, 2022, 323(5): H833-H844.
[55] Molofsky A B, Locksley R M. The ins and outs of innate and adaptive type 2 immunity[J]. Immunity, 2023, 56(4): 704-722.
[56] Paddock S J, Swift S K, Alencar-Almeida V, et al. IL4Rα signaling promotes neonatal cardiac regeneration and cardiomyocyte cell cycle activity[J]. J Mol Cell Cardiol, 2021, 161: 62-74.
[57] Alvarez-Argote S, Paddock S J, Flinn M A, et al. IL-13 promotes functional recovery after myocardial infarction via direct signaling to macrophages[J]. JCI Insight, 2024, 9(2): e172702.
[58] Liu J, Liu F L, Liang T T, et al. The roles of Th cells in myocardial infarction[J]. Cell Death Discov, 2024, 10(1): 287.
[59] Huang L Q. The role of IL-17 family cytokines in cardiac fibrosis[J]. Front Cardiovasc Med, 2024, 11: 1470362.
[60] Takahashi J, Yamamoto M, Yasukawa H, et al. Interleukin-22 directly activates myocardial STAT3 (signal transducer and activator of transcription-3) signaling pathway and prevents myocardial ischemia reperfusion injury[J]. J Am Heart Assoc, 2020, 9(8): e014814.
[61] Yamamoto M, Yasukawa H, Takahashi J, et al. Endogenous interleukin-22 prevents cardiac rupture after myocardial infarction in mice[J]. PLoS One, 2023, 18(6): e0286907.
[62] Liu F, Chen Y Q, Qin D M, et al. Interleukin-22 inhibits cardiac fibrosis by regulating fibroblast metabolic reprogramming in myocardial infarction[J]. Pathol Res Pract, 2024, 256: 155256.
[63] Yang Y, Li X Y, Li L C, et al. γδ T/interleukin-17A contributes to the effect of maresin conjugates in tissue regeneration 1 on lipopolysaccharide-induced cardiac injury[J]. Front Immunol, 2021, 12: 674542.
[64] Wang P, Kljavin N, Nguyen T T T, et al. Adrenergic nerves regulate intestinal regeneration through IL-22 signaling from type 3 innate lymphoid cells[J]. Cell Stem Cell, 2023, 30(9): 1166-1178.
[65] Weirather J, Hofmann U D, Beyersdorf N, et al. Foxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation[J]. Circ Res, 2014, 115(1): 55-67.
[66] Nayer B, Tan J L, Alshoubaki Y K, et al. Local administration of regulatory T cells promotes tissue healing[J]. Nat Commun, 2024, 15(1): 7863.
[67] Baccouche B M, Elde S, Wang H, et al. Structural, angiogenic, and immune responses influencing myocardial regeneration: a glimpse into the crucible[J]. NPJ Regen Med, 2024, 9(1): 18.
[68] Wang Y, Li J, Zhang Y, et al. AREG+ regulatory T cells mediating myocardial repair and neovascularization after myocardial infarction[J]. Mol Med, 2025, 31(1): 229.
[69] Courey-Ghaouzi A D, Kleberg L, Sundling C. Alternative B cell differentiation during infection and inflammation[J]. Front Immunol, 2022, 13: 908034.
[70] Tan Y, Duan X W, Wang B, et al. Murine neonatal cardiac B cells promote cardiomyocyte proliferation and heart regeneration[J]. NPJ Regen Med, 2023, 8(1): 7.
[71] Jiao J, He S J, Wang Y Q, et al. Regulatory B cells improve ventricular remodeling after myocardial infarction by modulating monocyte migration[J]. Basic Res Cardiol, 2021, 116(1): 46.
[72] Mo F R, Luo Y, Yan Y L, et al. Are activated B cells involved in the process of myocardial fibrosis after acute myocardial infarction? An in vivo experiment[J]. BMC Cardiovasc Disord, 2021, 21(1): 5.
[73] Marinkovi? G, Koenis D S, de Camp L, et al. S100A9 links inflammation and repair in myocardial infarction[J]. Circ Res, 2020, 127(5): 664-676.
[74] Sun Y Y, Pinto C, Camus S, et al. Splenic marginal zone B lymphocytes regulate cardiac remodeling after acute myocardial infarction in mice[J]. J Am Coll Cardiol, 2022, 79(7): 632-647.
[75] de Winter N, Ji J H, Sintou A, et al. Persistent transcriptional changes in cardiac adaptive immune cells following myocardial infarction: new evidence from the re-analysis of publicly available single cell and nuclei RNA-sequencing data sets[J]. J Mol Cell Cardiol, 2024, 192: 48-64.
[76] Yu X, Newland S A, Zhao T X, et al. Innate lymphoid cells promote recovery of ventricular function after myocardial infarction[J]. J Am Coll Cardiol, 2021, 78(11): 1127-1142.
文章导航

/